Comments
Loading...
Lifecore Biomedical Analyst Ratings and Price Targets | NASDAQ:LFCR | Benzinga
Lifecore Biomedical Inc has a consensus price target of $8 based on the ratings of 4 analysts. The high is $10 issued by Craig-Hallum on November 22, 2024. The low is $6 issued by Stephens & Co. on January 3, 2025. The 3 most-recent analyst ratings were released by Stephens & Co., Craig-Hallum, and Craig-Hallum on January 3, 2025, November 22, 2024, and September 5, 2024, respectively. With an average price target of $8 between Stephens & Co., Craig-Hallum, and Craig-Hallum, there's an implied -2.68% downside for Lifecore Biomedical Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Stephens & Co.
Craig-Hallum
1calculated from analyst ratings
Analyst Ratings for Lifecore Biomedical
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/21/2025 | Buy Now | — | William Blair | Max Smock21% | — | Initiates | → Outperform | Get Alert |
| 01/03/2025 | Buy Now | -27.01% | Stephens & Co. | Jacob Johnson59% | $6 → $6 | Reiterates | Equal-Weight → Equal-Weight | Get Alert |
| 11/22/2024 | Buy Now | 21.65% | Craig-Hallum | Matthew Hewitt73% | $8 → $10 | Maintains | Buy | Get Alert |
| 09/05/2024 | Buy Now | -2.68% | Craig-Hallum | Matthew Hewitt73% | → $8 | Initiates | → Buy | Get Alert |
| 08/28/2024 | Buy Now | — | Barrington Research | Michael Petusky50% | — | Downgrade | Outperform → Market Perform | Get Alert |
| 09/01/2023 | Buy Now | 21.65% | Barrington Research | Michael Petusky50% | $11 → $10 | Maintains | Outperform | Get Alert |
| 09/01/2023 | Buy Now | 9.49% | Stephens & Co. | Jacob Johnson59% | $8 → $9 | Maintains | Equal-Weight | Get Alert |
| 06/02/2023 | Buy Now | 33.82% | Barrington Research | Michael Petusky50% | $10 → $11 | Maintains | Outperform | Get Alert |
| 05/24/2023 | Buy Now | 21.65% | Barrington Research | Michael Petusky50% | $8 → $10 | Maintains | Outperform | Get Alert |
| 03/21/2023 | Buy Now | -2.68% | Barrington Research | Michael Petusky50% | $10 → $8 | Maintains | Outperform | Get Alert |
| 03/20/2023 | Buy Now | -2.68% | Barrington Research | Michael Petusky50% | $10 → $8 | Maintains | Outperform | Get Alert |
| 03/20/2023 | Buy Now | -75.67% | Stephens & Co. | Jacob Johnson59% | $11 → $2 | Downgrade | Overweight → Equal-Weight | Get Alert |
| 03/17/2023 | Buy Now | 33.82% | Stephens & Co. | Jacob Johnson59% | → $11 | Reiterates | → Overweight | Get Alert |
FAQ
What is the target price for Lifecore Biomedical (LFCR) stock?
The latest price target for Lifecore Biomedical (NASDAQ:LFCR) was reported by William Blair on May 21, 2025. The analyst firm set a price target for $0.00 expecting LFCR to fall to within 12 months (a possible -100.00% downside). 5 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Lifecore Biomedical (LFCR)?
The latest analyst rating for Lifecore Biomedical (NASDAQ:LFCR) was provided by William Blair, and Lifecore Biomedical initiated their outperform rating.
When was the last upgrade for Lifecore Biomedical (LFCR)?
There is no last upgrade for Lifecore Biomedical
When was the last downgrade for Lifecore Biomedical (LFCR)?
The last downgrade for Lifecore Biomedical Inc happened on August 28, 2024 when Barrington Research changed their price target from N/A to N/A for Lifecore Biomedical Inc.
When is the next analyst rating going to be posted or updated for Lifecore Biomedical (LFCR)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Lifecore Biomedical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Lifecore Biomedical was filed on May 21, 2025 so you should expect the next rating to be made available sometime around May 21, 2026.
Is the Analyst Rating Lifecore Biomedical (LFCR) correct?
While ratings are subjective and will change, the latest Lifecore Biomedical (LFCR) rating was a initiated with a price target of $0.00 to $0.00. The current price Lifecore Biomedical (LFCR) is trading at is $8.22, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
